Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia

Angelescu I, Kaar SJ, Marques TR, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. Journal of Psychopharmacology. 2022;36(9):1061-1069. doi:10.1177/02698811221122031